ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics LLC announced today that it has been identified and selected by Therapeutic Area Partnerships as a “Top Project to Watch: Most Licensable Products” for the second consecutive year. RetroSense Therapeutics is a privately held biotechnology company at the forefront of developing optogenetic therapies for vision restoration. In October 2014, RetroSense’s lead compound, RST-001 was granted orphan drug designation for retinitis pigmentosa, a genetic disease characterized by deteriorating vision and blindness.
Sean Ainsworth, CEO of RetroSense Therapeutics, presented a corporate overview on behalf of the Company in the “Advanced Therapeutics” category at the Therapeutic Area Partnerships conference today at the Hyatt Regency Hotel in Boston, MA.
The Top Projects to Watch are “hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products”.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.”
“We are thrilled to receive this accolade for the second consecutive year,” said Mr. Ainsworth. “We continue to achieve development milestones for our lead compound RST-001 and expect that the orphan drug designation should facilitate our additional development efforts, which we intend to discuss at the Therapeutic Area Partnerships Conference.”
About RetroSense Therapeutics
RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The Company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through to the clinic. For more information about RetroSense, visit http://www.retro-sense.com/.